BioCentury | Feb 12, 2021
Product Development

Tau vaccine moving toward late-stage trials for Alzheimer’s

...chronic diseases.In Alzheimer’s disease, vaccines have had a checkered history, with an early candidate from Elan...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

...Jesper Høiland will step down. He is succeeded by Kelly Martin, who was CEO of Elan...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...as CEO of the Aranta Therapeutics Inc. pet therapeutics unit of Elanco Animal Health (NYSE: ELAN...
BioCentury | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

...it will pursue. The Rodin deal marks Alkermes' first acquisition since its 2011 takeout of Elan...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

...amyloid; PET = positron emission topography imaging of amyloid plaques using radiolabeled contrast agents; (A) Elan Corp. plc...
...Product Target Trial Data reported Population Pts Duration Cognition result Amyloid result Amyloid measure Completed? Elan Corp. plc...
...to the compound, the target or the trial design. The first big failure came from Elan Corp. plc...
BioCentury | Dec 14, 2018
Company News

Mereo, OncoMed announce merger

Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ....
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...He will start as EVP and CFO on Nov. 1 at Elanco Animal Health Inc. (NYSE:ELAN...
BioCentury | Sep 28, 2018
Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
Items per page:
1 - 10 of 2285
BioCentury | Feb 12, 2021
Product Development

Tau vaccine moving toward late-stage trials for Alzheimer’s

...chronic diseases.In Alzheimer’s disease, vaccines have had a checkered history, with an early candidate from Elan...
BioCentury | Apr 30, 2020
Management Tracks

Desmond-Hellmann joins GV as adviser; plus Radius, Anika, AMAG, AiCure and more

...Jesper Høiland will step down. He is succeeded by Kelly Martin, who was CEO of Elan...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

Insmed rose $8.34 (41%) to $28.88 on Monday, gaining $745 million in market cap, after its chronic lung inflammation therapy met the primary endpoint in a Phase II study. But the data, which included an...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...as CEO of the Aranta Therapeutics Inc. pet therapeutics unit of Elanco Animal Health (NYSE: ELAN...
BioCentury | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

...it will pursue. The Rodin deal marks Alkermes' first acquisition since its 2011 takeout of Elan...
BioCentury | May 4, 2019
Product Development

Amyloid: how did we get here and what can we learn?

...amyloid; PET = positron emission topography imaging of amyloid plaques using radiolabeled contrast agents; (A) Elan Corp. plc...
...Product Target Trial Data reported Population Pts Duration Cognition result Amyloid result Amyloid measure Completed? Elan Corp. plc...
...to the compound, the target or the trial design. The first big failure came from Elan Corp. plc...
BioCentury | Dec 14, 2018
Company News

Mereo, OncoMed announce merger

Mereo BioPharma Group plc (LSE:MPH) announced a merger with OncoMed Pharmaceuticals Inc. (NASDAQ:OMED); the resulting entity will focus on development of Mereo's orphan disease pipeline and will be listed on London Stock Exchange and NASDAQ....
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...He will start as EVP and CFO on Nov. 1 at Elanco Animal Health Inc. (NYSE:ELAN...
BioCentury | Sep 28, 2018
Preclinical News

Two strategies block immune-mediated metastases in mice

Cold Spring Harbor Laboratory researchers and a team from two Italian institutions have published two different strategies to fight immune-mediated lung metastases. Dormant cancer cells can persist for years before awakening and proliferating, leading to...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
Items per page:
1 - 10 of 2285